drugset / Trial / NCT07539610
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of Sup19 CAR-T cells in cases where previous CD19-targeted therapy has failed or where CD19 Evaluation of Safety and Efficacy in the Treatment of Low-Grade Hematological Malignancies: A Prospective, Single-Arm Clinical Study Research
Timeline
- Start
- 2026-04
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sup19 CAR-T | Cell therapy | 0.5 cells/kg | — |
| Subject | Sup19 CAR-T | Cell therapy | 1 cells/kg | — |
| Subject | Sup19 CAR-T | Cell therapy | 3 cells/kg | — |